Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
NCT06807437 · View on ClinicalTrials.gov ↗
Study Summary
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Saline
- OTHER Questionnaire Administration
- PROCEDURE Distal Pancreatectomy
- DRUG Lanreotide
Study Locations (20)
Illinois
- Northwestern University — Chicago
- University of Illinois — Chicago
- Northwestern Medicine Cancer Center Delnor — Geneva
- Northwestern Medicine Oak Brook — Oak Brook
- Northwestern Medicine Orland Park — Orland Park
- Northwestern Medicine Cancer Center Warrenville — Warrenville
Delaware
- Helen F Graham Cancer Center — Newark
- Medical Oncology Hematology Consultants PA — Newark
- Christiana Care Health System-Christiana Hospital — Newark
- Christiana Care Health System-Wilmington Hospital — Wilmington
Georgia
- Grady Health System — Atlanta
- Emory University Hospital Midtown — Atlanta
- Emory University Hospital/Winship Cancer Institute — Atlanta
- Emory Saint Joseph's Hospital — Atlanta
California
- UC San Diego Moores Cancer Center — La Jolla
- USC / Norris Comprehensive Cancer Center — Los Angeles
- UC San Diego Medical Center - Hillcrest — San Diego
Alabama
- University of Alabama at Birmingham Cancer Center — Birmingham
- Mobile Infirmary Medical Center — Mobile
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2025-05-09 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06807437
The ClinicalTrials.gov registry entry for NCT06807437 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Pancreatic Carcinoma appearing as the primary indexed condition, and to 5 interventions — of which Biospecimen Collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06807437 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Illinois, Delaware, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06807437 about?
NCT06807437 is a clinical study titled "Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula". This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by t...
What is the current status of trial NCT06807437?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2025-05-09. Estimated completion is 2027-11-01.
What conditions does trial NCT06807437 study?
This clinical trial studies the following conditions: Pancreatic Carcinoma, Pancreatic Neoplasm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06807437?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Saline (OTHER), Questionnaire Administration (OTHER), Distal Pancreatectomy (PROCEDURE), Lanreotide (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06807437?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06807437 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.